Jayex Healthcare Revises NZ Medicinal Cannabis Plan Following MediCann Collapse


On March 18, Jayex Healthcare (ASX: JHL) revised their strategy to access the New Zealand market, including cultivation and manufacturing, while implementing their medicinal cannabis prescription processing and remote dispensing technology.

This announcement follows the liquidation of MediCann, with whom JHL had licensed their technology for New Zealand.

Now, rather than rely on third parties, JHL has created a subsidiary in New Zealand to handle commercialisation – Whakaora Hou Limited.

Since MediCann fell apart, Whakaora Hou has applied for a cultivation research licence, leased land in Papamoa, and engaged with Ross Smith and his New Zealand company, Weed Inc.

Ross Smith was a director of MediCann, and has been heavily involved in the medicinal cannabis industry in Australia and New Zealand for some time, although at times this has been somewhat controversial.

JHLs key technology is the BluePoint Kiosk, a remote dispensing terminal that JHL will fill with their own medicinal cannabis products, once approved for use in New Zealand. Since late last year, they have been focussed on demonstrating the advantages of this technology to doctors and pharmacists.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”